Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2019-11-07 | Reverse | 1:10 |
| 2019-07-15 | Forward | 1011:1000 |
| 2016-12-28 | Reverse | 3:10 |
Immutep Limited is an Australian biotech company developing immunotherapies for cancer and autoimmune diseases, with multiple clinical-stage products and collaborations with major pharma companies.

Eftilagimod alpha is Immutep's lead soluble LAG-3 fusion protein immunotherapy, currently in multiple clinical trials including Phase III for non-small cell lung cancer, designed to activate antigen-presenting cells and stimulate anti-cancer immun...
Overall rating: C
| PEER | PRICE | |
|---|---|---|
CADL | $13.07 | COMPARE |
ACHV | $8.10 | COMPARE |
ALLO | $2.02 | COMPARE |
CAPR | $9.59 | COMPARE |
CABA | $3.12 | COMPARE |
EDIT | $3.16 | COMPARE |
VNDA | $5.29 | COMPARE |
TRDA | $7.00 | COMPARE |